Investigating Pirfenidone and Vitamin D for Targeting Cardiac and Renal Fibrotic Pathways in Experimentally-Induced Animal Model
Antar, S., El-Azab, M., hazem, R., saleh, M. (2019). Investigating Pirfenidone and Vitamin D for Targeting Cardiac and Renal Fibrotic Pathways in Experimentally-Induced Animal Model. EKB Journal Management System, 3(1), 11-16. doi: 10.21608/rpbs.2019.5575.1015
Samar Antar; Mona Farag El-Azab; reem hazem; Mohamed saleh. "Investigating Pirfenidone and Vitamin D for Targeting Cardiac and Renal Fibrotic Pathways in Experimentally-Induced Animal Model". EKB Journal Management System, 3, 1, 2019, 11-16. doi: 10.21608/rpbs.2019.5575.1015
Antar, S., El-Azab, M., hazem, R., saleh, M. (2019). 'Investigating Pirfenidone and Vitamin D for Targeting Cardiac and Renal Fibrotic Pathways in Experimentally-Induced Animal Model', EKB Journal Management System, 3(1), pp. 11-16. doi: 10.21608/rpbs.2019.5575.1015
Antar, S., El-Azab, M., hazem, R., saleh, M. Investigating Pirfenidone and Vitamin D for Targeting Cardiac and Renal Fibrotic Pathways in Experimentally-Induced Animal Model. EKB Journal Management System, 2019; 3(1): 11-16. doi: 10.21608/rpbs.2019.5575.1015

Investigating Pirfenidone and Vitamin D for Targeting Cardiac and Renal Fibrotic Pathways in Experimentally-Induced Animal Model

Records of Pharmaceutical and Biomedical Sciences
Article 3, Volume 3, Issue 1, March 2019, Page 11-16  XML PDF (432.06 K)
Document Type: Mini-reviews
DOI: 10.21608/rpbs.2019.5575.1015
View on SCiNiTO View on SCiNiTO
Authors
Samar Antar email 1; Mona Farag El-Azaborcid 2; reem hazem3; Mohamed saleh4
1Department of Pharmacology and Toxicology, Faculty of pharmacy -Horus university, Damietta, Egypt
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt
3Department of pharmacology and toxicology ,faculty of pharmacy ,Suez Canal University ,Ismailia,Egypt
4Department of pharmacology and Toxicology,Faculty of pharmacy,Mansura University, Mansura,Egypt
Abstract
Breast cancer is considered as the most familiar cancer in females which represented 38.8 % in Egypt and 29% in the world. It is the second common cause of cancer-related death in women. Treatment of breast cancer with chemotherapeutic agent as Doxorubicin may lead to many side effects, mainly cardiac and renal fibrosis. The present study aimed to investigate the underlying molecular mechanisms for the potential anti-fibrotic effect of pirfenidone (500mg/kg, P.O. once daily) and Vitamin D (0.5µg/kg I.P. once daily) against doxorubicin (15 mg/kg I.P.) induced cardio- and renal- fibrosis. Moreover, the anti-cancer potential of pirfenidone (PFD) and Vitamin D either alone or in combination with doxorubicin will be assessed in a xenograft experimental model of breast cancer. Then, tissue and blood samples will be collected after two weeks post-treatment to assess the toxicity of Doxorubicin and to determine how pirfenidone and vitamin D protect against the toxicity of Doxorubicin .
Keywords
breast cancer; Doxorubicin; Pirfenidone; Vitamin D
Statistics
Article View: 318
PDF Download: 297